GlassScriptPhysician profile
Erin Dean
NPI 1316335870
$3,600.28
in general payments reported to CMS, 2019-2025
34 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $282 · 2023: $762 · 2024: $1,171 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.68 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $576.04 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $571.22 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $349.98 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $295.99 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $244.22 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.59 | 2023-2025 | Xifaxan |
| Lundbeck LLC | $120.68 | 2023-2025 | Rexulti |
| Amgen INC. | $116.14 | 2023-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $105.92 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $103.06 | 2022-2025 | |
| Seagen INC. | $99.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.21 | 2025 | Caplyta |
| Dexcom, INC. | $82.42 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $73.95 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $70.66 | 2022-2025 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $66.23 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Abiomed | $58.07 | 2024 | Impella |
| Axsome Therapeutics, INC. | $31.74 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $31.73 | 2022-2023 | Quviviq |
| Inspire Medical Systems, INC. | $31.15 | 2023 | Inspire |
| Ani Pharmaceuticals, INC. | $30.90 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $30.60 | 2025 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $27.86 | 2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $26.40 | 2022 | |
| Sanofi Pasteur INC. | $25.99 | 2024 | |
| Neurelis, INC. | $24.87 | 2025 | Valtoco |
| Insulet Corporation | $24.67 | 2025 | Omnipod |
| Azurity Pharmaceuticals, INC. | $22.34 | 2024 | Edarbi |
| Teva Pharmaceuticals USA, INC. | $22.26 | 2022 | |
| Glaxosmithkline, LLC. | $21.74 | 2022 | |
| Boston Scientific Corporation | $20.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.02 | 2022 | |
| Alkermes, INC. | $16.20 | 2023 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.